Phase I Trial of Dasatinib, Lenalidomide, and Temozolomide in Children with Relapsed or Refractory Central Nervous System Tumors

BACKGROUND: Single agent studies targeting the tumor microenvironment in central nervous system (CNS) tumors have largely been disappointing. Combination therapies targeting various pathways and cell types may be a more effective strategy. In this phase I study, we evaluated the combination of dasat...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Neurooncol
Egile Nagusiak: Robison, Nathan J., Yeo, Kee Kiat, Berliner, Adrian P., Malvar, Jemily, Sheard, Michael A., Margol, Ashley S., Seeger, Robert C., Rushing, Teresa, Finlay, Jonathan L., Sposto, Richard, Dhall, Girish
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2018
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5930136/
https://ncbi.nlm.nih.gov/pubmed/29427149
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-018-2791-y
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak